ValueREAD: The first universal rapid test platform enabled with Artificial Intelligence
IDNEO proposes the innovative and attractive vision of an AI-powered universal reader platform that keeps the advantages of using rapid tests for the detection of SARS-CoV-2 antigen with solving some of the needs in the fight against COVID-19;
● Product family configurable to support a wide variety of vendors and rapid test products.
● A single device that clinical / test centers will use to process COVID-19 and other rapid tests from multiple sources.
● Robust analytical process, typical of more sophisticated test platforms, including automated test interpretation, full patient / result traceability and connectivity.
● Support to COVID-19 clinical use cases for the determination of the patient’s immune status, epidemiological studies, and other diagnostics.
● Expandability to accommodate innovative and rapidly evolving rapid test formats and methods (microarrays, dot arrays…)
● Data digitisation to enable further analysis, valuable for real-time and epidemiological studies, prospective and retrospective clinical trials, and potential integration with patient electronic health records.